Feel free to contact us if you would like additional information that is not provided in this or our Investor Relations website.

Human BioSystems trades under the symbol: HBSC:OTCBB

INVEST IN THE FUTURE TODAY
Human BioSystems transforms preservation technology with simple and efficient systems for platelets and organs.

Human BioSystems, (OTC-BB:HBSC) has pioneered revolutionary technologies that may forever change both the blood banking and organ and tissue transplantation industries. Developed after many years of research into extending the preservation periods of biological materials, these cutting-edge technologies may soon be available to save potentially thousands of lives and hundreds of millions of dollars.

FOR PLATELETS: THE MIRACLE COMPONENT OF BLOOD
The Human BioSystems biological preservation program is a technologically advanced preservation and storage system. It extends the life of platelets, the congealing component of blood. Cancer patients undergoing chemotherapy treatments are the predominant recipients of platelet transfusions. Other persons that often require platelet transfusions are patients undergoing extensive surgery, trauma or burn victims, and individuals with platelet deficiencies such as caused by bone marrow disease.

Currently, platelet storage time is limited to a maximum of five days as mandated by the FDA, due to the fact that they are stored at room temperature which creates potential bacterial problems and a loss of platelet functionality. Thousands of units of platelets are discarded at the end of the five-day period, creating shortages and wasting extraordinary amounts of money. Platelets older than three days may contain a high bacterial count causing a risk of infection to patients. In Japan government regulation requires that all platelets be used within three days.

The FDA presently requires blood banks to perform tests to screen for viral diseases, which can take up two days. Bacterial testing has not been mandated due to the short period of time remaining for infusion. However, this situation may change because of consumer and government pressure to have blood centers and hospitals do testing for bacteria. If the FDA rules in favor of this, it will undoubtedly cause many problems for the blood industry.

Our goal is to change this storage dilemma. Our unique patent- pending technology could double the storage period for platelets, may dramatically reduce bacterial growth and may maintain better platelet functionality. Upon further development and regulatory approvals, we expect to be a major supplier to the industry with our improved platelet storage technology.

FOR ORGANS: BREAKTHROUGH PRESERVATION TECHNOLOGY
The Human BioSystems organ preservation system is a technologically advanced storage program. It promises to dramatically extend the shelf life of hearts, kidneys, lungs, livers and pancreas.

Today, the most effective treatment for patients with organ failure is to surgically replace the failed organ with a viable donated organ from a living person or from a cadaver donor. Organ transplantation can save or improve the quality of life for many patients.

The increasing number of organ transplantations requires more available organs and increases the need to store donor organs. Testing and transportation time to get the best possible match of organ to the recipient increase the need for improved organ storage methods compared to current technology.

We are dedicated in becoming the leading supplier of extended organ preservation technology. With currently applied preservation methods, the human heart and lungs are viable for only four to six hours, whereas the liver and the pancreas can be preserved marginally longer. Kidneys are stored on ice for up to 24-36 hours. Our goal is to extend shelf life of organs from hours to days while maintaining viability, safety, and quality for successful transplantation, reduce hospital stays and allow for scheduled procedures to be the rule versus emergency procedures. In contrast, expensive perfusion systems can extend the viability of the human heart for only a few hours longer than is possible with a simple ice chest.

The availability of longer preservation times though our preservation technology will facilitate closer donor/recipient organ-matching criteria, reduce or eliminate organ spoilage, and provide ample time to transport the organ, regardless of the location of either the donor or recipient.

We envision our proprietary technique to be at the forefront of organ preservation technology. HBS's opportunity in the blood platelet market is expected to exceed 300 million 2007 and further expected to grow an additional ten percent each year thereafter.